Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who ...

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months through 11 years. Novavax's COVID shot (Nuvaxovid) is fully approved for people ...

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Novavax, Inc. announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid for active immunization to prevent coronavirus disease 2019 ...

Nuvaxovid is a vaccine indicated for active immunization to prevent Covid-19 caused by SARS-CoV-2 in adults 65 years and older and individuals 12 through 64 years who have at least one underlying ...

The FDA’s approval of Nuvaxovid™, which is not based on mRNA technology, has triggered a milestone payment of $175 million to Novavax from its collaborator Sanofi. This partnership, established in May ...

Nuvaxovid™, which targets the JN.1 variant of the virus, has been available in the U.S. under Emergency Use Authorization since July 2022. It has also received full market approvals in several ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment related to the 2024/2025 season, annual ...